Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Businessweek Archives

Genentech's Change Of Heart


In Business This Week

GENENTECH'S CHANGE OF HEART

Just a few years ago, Genentech argued that a version of the heart attack drug TPA made by Wellcome was so like its own that it sued for patent infringement--and won. Now, the biotech pioneer is screaming that TPA and the Wellcome version, known as duteplase, are as different as night and day. In fact, on Feb. 25, it filed suit against another rival, SmithKline Beecham, for implying in promotional materials that Genentech's TPA and duteplase were equivalent.

Why the flip-flop? A new study unveiled on Mar. 2 found that three TPA rivals, including duteplase, are roughly equivalent in reducing deaths from heart attacks. All three cost much less than Genentech's version, which last year accounted for 44% of the company's $476 million in revenues.EDITED BY HARRIS COLLINGWOOD


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus